NewAmsterdam Pharma Company N.V./$NAMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Ticker
$NAMS
Sector
Primary listing
Employees
68
Headquarters
Website
NAMS Metrics
BasicAdvanced
$3.5B
-
-$1.55
-0.01
-
Price and volume
Market cap
$3.5B
Beta
-0.01
52-week high
$31.81
52-week low
$14.06
Average daily volume
968K
Financial strength
Current ratio
21.085
Quick ratio
20.785
Long term debt to equity
0.013
Total debt to equity
0.042
Profitability
EBITDA (TTM)
-172.616
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-258.91%
Operating margin (TTM)
-269.96%
Effective tax rate (TTM)
0.00%
Revenue per employee (TTM)
$940,000
Management effectiveness
Return on assets (TTM)
-17.12%
Return on equity (TTM)
-28.43%
Valuation
Price to revenue (TTM)
51.38
Price to book
4.43
Price to tangible book (TTM)
4.44
Price to free cash flow (TTM)
-26.456
Free cash flow yield (TTM)
-3.78%
Free cash flow per share (TTM)
-1.159
Growth
Revenue change (TTM)
762.15%
Earnings per share change (TTM)
-41.36%
3-year revenue growth (CAGR)
-16.47%
3-year earnings per share growth (CAGR)
-1.18%
Bulls say / Bears say
Late-breaking BROADWAY and TANDEM Phase 3 trial results presented at the European Atherosclerosis Society Congress—and published simultaneously in The New England Journal of Medicine and The Lancet—confirmed significant reductions in LDL-C, with a safety profile similar to placebo, highlighting obicetrapib’s unique efficacy and tolerability.
The European Medicines Agency validated Marketing Authorization Applications for both 10 mg obicetrapib as monotherapy and as a fixed-dose combination with ezetimibe in August 2025, moving the drug forward in the regulatory review process and preparing for a potential launch in Europe.
A prespecified analysis of Alzheimer’s disease biomarkers presented at AAIC in July 2025 showed obicetrapib significantly lowered plasma p-tau217 levels (p=0.0019) across all patients and in ApoE4 carriers (p=0.0215), indicating possible neuroprotective effects in addition to lowering cholesterol.
Selling, general, and administrative expenses rose 65.5% year-over-year to $27.3 million in Q2 2025 as NewAmsterdam expanded its commercial operations, increasing cash outflows before product revenue begins.
Under the Menarini license, NewAmsterdam may receive up to €863 million in milestone payments and tiered royalties from European sales, which introduces revenue uncertainty due to the lack of definite product launch dates.
NewAmsterdam's shares are trading near a 52-week high of $27.29 with a forward P/E of 14.72, suggesting limited upside unless more positive clinical developments emerge.
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NewAmsterdam Pharma Company N.V. stock?
NewAmsterdam Pharma Company N.V. (NAMS) has a market cap of $3.5B as of October 05, 2025.
What is the P/E ratio for NewAmsterdam Pharma Company N.V. stock?
The price to earnings (P/E) ratio for NewAmsterdam Pharma Company N.V. (NAMS) stock is 0 as of October 05, 2025.
Does NewAmsterdam Pharma Company N.V. stock pay dividends?
No, NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders as of October 05, 2025.
When is the next NewAmsterdam Pharma Company N.V. dividend payment date?
NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders.
What is the beta indicator for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. (NAMS) has a beta rating of -0.01. This means that it has an inverse relation to market volatility.